Overview

Evaluation of N1539 Following Abdominoplasty Surgery

Status:
Completed
Trial end date:
2016-11-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the analgesic efficacy of N1539 in subjects with acute moderate to severe pain following abdominoplasty surgery.
Phase:
Phase 3
Details
Lead Sponsor:
Recro Pharma, Inc.
Treatments:
Meloxicam